Categoría: Geovanny Vicente

FREDERICK, Md., Aug. 11, 2020 /PRNewswire-PRWeb/ — The emergence of the novel coronavirus SARS‐CoV‐2 and the resulting COVID‐19 pandemic has made the development of therapeutics, vaccines, and potential cures one of the scientific research community’s top priorities. XpressBio recently provided key products, including its COVID-19 S1/S2 microplate and ELISA reagents, to one of the world’s preeminent non-human primate research centers, the California National Primate Research Center (CNPRC), for a surveillance program to determine the viral status of its non‐human primate breeding colony at the University of California, Davis. XpressBio researcher William Boteler and his team also provided scientific consulting services, including a comparison of sample activities to a panel of Coronavirus antigens prepared in different cell lines.

One of seven such centers supported by the National Institutes of Health, the California National Primate Research Center has the nation’s best-characterized population of older primates—an important edge in evaluating how age affects the impact of coronavirus on vulnerable older adults with long-term conditions like hypertension and Type-2 diabetes. Considering the similarity between human and non-human primate physiology, especially with regard to respiratory systems and immune/aging patterns, the results from this study were integral in preserving and maintaining the colony’s health as well as providing information critical to the development of new COVID-19 drugs, therapies, and surgical procedures.

Approximately 2,450 animals are housed outdoors and 1,300 indoors at the CNPRC. A sentinel surveillance program to test at least 10% of the CNPRC colony– 385 animals housed in 73 different indoor rooms or outdoor enclosures—was conducted in March, April, and May 2020. 256 paired blood and swab samples were tested for SARS‐CoV‐2 antibody and RNA.

The study had important implications related to the epidemiology of SARS‐CoV‐2 in the human population and primate populations, risk of virus introduction and transmission, especially from asymptomatic carriers, and the most important components of effective infection control programs.

«Studies like this one are critically important to understanding how we can prevent and treat COVID-19, as well as future coronavirus outbreaks,» said XpressBio President and CEO Mo Hashemzadeh. «Information being gathered now will also be equally important in strategizing a more effective defense against potential new viral pandemics that may emerge in the future.»

Details of the study are available at: https://onlinelibrary.wiley.com/doi/full/10.1111/jmp.12483

Read XpressBio’s SARS-CoV-2 COVID-19 Protein Plate White Paper at:
https://xpressbio.com/news/sars-cov-2-covid-19-protein-plate-white-paper/

SOURCE XpressBio

STOCKTON, Calif., Aug. 11, 2020 /PRNewswire-PRWeb/ — California criminal defense attorney Allen Sawyer of the Law Offices of Allen Sawyer announced today that Case # CR-2019-4210705 in San Joaquin County Superior Court was settled after District Attorney Tori Verber Salazar reduced the charges for his client from felony to misdemeanor.

At the start of the jury trial, Sawyer’s client, Brian W., faced charges of contacting a minor to commit a felony and of arranging a meeting with a minor for lewd purposes. Sawyer’s opening arguments, legal motions, and exposure of evidentiary issues contributed to the DA’s reduction of the charges to misdemeanor.

The arrest of, and the charges against, Brian W. stemmed from a police decoy scenario. In such scenarios a police officer posing as a worker for an escort service extends sexual services to a text responder. After an agreement is reached, the officer claims to be a minor. Text responders who still agree to meet for the purpose of sexual services are arrested. Such an arrest brings felony charges that carry serious state prison sentences as well as lifetime sex offender registration.

Sawyer said the victory came as a great relief for his client. «It went from a state prison case with lifetime registration to a misdemeanor with suspended fine and no additional jail time,» he said. «We are very pleased with the outcome.»

About California Defense Attorney Allen Sawyer
With offices in Stockton, San Jose, and Sacramento, The Law Offices of Allen Sawyer comprise unparalleled attorney representation for a range of legal matters across the state. Additionally, Mr. Sawyer can be seen regularly on local television news, handling cases for politicians, celebrities, sports figures, and matters in the public eye.

Misdemeanors and felonies, Allen Sawyer litigates California criminal defense cases including, but not limited to, the following categories:

• Criminal Defense
• Drug Crimes Defense
• Embezzlement Defense
• Federal Crimes Defense
• White Collar Defense

Mr. Sawyer fights for the rights of the accused. For more information or to schedule a consultation, please contact Allen Sawyer directly at (209) 645-0556, or visit the law firm website: https://www.allensawyer.com/.

Press release writing by WebSiteText and Proofreading Services by The Proofreaders.

SOURCE Attorney Allan Sawyer

MESA, Ariz., Aug. 11, 2020 /PRNewswire/ — mySongbird is modernizing the concert experience with its new concert streaming platform and restoring our planet through the power of music.

The music industry is changing, and mySongbird’s team, which together boasts over a century of experience across music, technology, and entertainment, rose to the challenge. Even before the coronavirus gripped the music industry, canceling tours and in-person concerts, streaming was on the rise. Now, in a post-COVID world, live-streaming is gaining even more steam, up 99% this year alone. mySongbird set out to fill the void and has created a revolutionary, sustainable company harnessing the power of music to change the world for the better.

The mySongbird model is a win for everyone. Subscribers will gain access to immersive experiences through a library of past, present and future shows across numerous languages and genres. Artists will enjoy connecting with more fans and earning more income. The planet will also benefit. A minimum of 20% of mySongbird’s EBITDA will be reinvested in companies or individuals who are working on technological solutions to ensure that Planet Earth lives on indefinitely. They will seek out the greatest ideas, help entrepreneurs in their start-up phases, fund the best of these companies, and assist in their growth.

mySongbird will begin hosting safely-distanced, intimate performances this fall, meeting fans where they are through television, phones, laptops, desktop computers, tablets and more. The performances will live on after the encore, with fans able to re-watch on the mySongbird site as well as on Dish, Sling and other platforms.

Founder and CEO, Michael Mountford, said, «I created mySongbird because I realized that people pay to attend a sporting event, and then come home to watch sports on TV, but this wasn’t the case for concerts. At the same time, I also thought about how a large portion of professional athletes’ income is derived from huge TV contracts, and again, this wasn’t the case for the music industry and musicians. mySongbird was the answer to solving both of these things, and I am excited to be able to support artists and fans all while giving back to our planet.»

About mySongbird

Founded in 2020 by Michael Mountford, mySongbird is a sustainable company filling the void of premium musical entertainment on television. By providing in-person and streamed concerts, and a massive genre-spanning library, the company is able to support artists and fans simultaneously with a professionally-produced, fully immersive style. The company is also serious about doing the most good. mySongbird reinvests a minimum of 20% of their EBITDA in companies or individuals who are working on technological solutions to ensure that Planet Earth lives on indefinitely. They will seek out the greatest ideas, help entrepreneurs in their start-up phases, fund the best of these companies, and assist in their growth. 

For additional information please visit, https://mysongbird.com/.

View original content:http://www.prnewswire.com/news-releases/mysongbird-modernizes-the-concert-experience-while-restoring-the-planet-through-the-power-of-music-301109517.html

SOURCE mySongbird

PELHAM, N.Y., Aug. 11, 2020 /PRNewswire-PRWeb/ — More than 50% of US K-12 public school students will be attending school remotely to start the school year, according to a comprehensive, ongoing survey conducted by Burbio.com, a data service that aggregates school and community calendars nationwide. Specifically, 52% of students are projected to be learning online to start the year, 44% will be attending in-person either every day or certain days of the week, and 4% of students are in school districts that haven’t finalized plans.

«We have seen a dramatic shift to online only learning in the past three weeks,» said Burbio co-founder Julie Roche. «Large districts such as Chicago, and Sun Belt cities such as Houston and Miami along with large suburban districts such as Fairfax County Virginia were all setting plans to return with in-person learning and shifted to fully remote.»

Burbio’s data set consists of more than 80,000 K-12 school calendars across all 50 states and is dynamically updated as events are added or changed. For this initiative, Burbio actively monitors districts representing over 35,000 schools, including the 200 largest school districts in the U.S. District plans are reviewed every 72 hours to identify changes. School districts in the data set are a mix of sizes and distributed nationally in such a way to represent local decision-making across the country.

Size of district is a big factor in the approach districts are taking. The 200 largest districts are 66% virtual. The survey assumes New York City, the largest school district in the country, holds in-person schooling as announced and recently approved by Gov. Andrew Cuomo.

Breaking down the 44% in-person, approximately 19% of students nationally will be attending a hybrid format where students only attend certain days. Twenty five percent will go to school daily, meaning one quarter of K-12 public school students in the country will be attending school every day to start the year.

«We expect this situation to stay fluid for the entire academic year and we will continue to measure it,» said Roche. «Many districts have thresholds for Covid-19 levels that could result in converting back to remote learning. Other districts are planning to revisit the ‘on-line’ decision as soon as September and could convert to in-person models.»

About the Methodology

Margin for error is 2.73% at 95% confidence level. For detailed methodology visit https://about.burbio.com/methodology/ or email dennis@burbio.com

About Burbio:

Burbio.com is the industry leader in aggregating school, government, library and community event information for digital consumer engagement and business decision making. Burbio’s technology organizes and streams millions of hyper-local events across the US and keeps them automatically updated. Burbio’s relevant and critical content is engaging for consumers and important for business decision making. In addition to the Burbio.com consumer service, Burbio works with digital media companies, local broadcasters, real estate firms, government and library partners, national non-profits, corporate clients and investment professionals who use this community event information to engage consumers and better manage and predict their business.

SOURCE Burbio, Inc

WALNUT CREEK, Calif., Aug. 11, 2020 /PRNewswire-PRWeb/ — Conductiv™, the leading third-party spend optimization solutions provider, announced today an initiative to help healthcare providers better identify and increase their spend with local and minority-owned suppliers.

As local, minority-owned suppliers have struggled with the economic impact of COVID-19, and the public advocates for businesses that promote greater equality, Conductiv’s latest enhancement offers diverse suppliers an effective and proven way to grow their businesses, while enabling providers to encourage and promote diversity with their third-party service providers.

«Healthcare providers are looking to support a more diverse and inclusive roster of suppliers—including community-led minority-, women- and veteran-owned businesses—but it can often be difficult to identify diverse suppliers with capabilities needed within the healthcare industry,» said Conductiv CEO Chris Gormley. «Recognizing both the importance and need for national change in this moment, we immediately deployed a team of developers to create technology enhancements that enable Conductiv’s members to increase their percentage of spend with diverse and local suppliers. Studies have shown that population health and economic performance are correlated and hold influence over social and environmental outcomes.»

Conductiv will anchor this initiative by adding diversity analytics to its integrated third-party services optimization suite—allowing for immediate visibility of Tier 1 and Tier 2 local and minority-owned supplier spending and new suppliers. Customers will have the ability to precisely measure their diverse supplier spending and efficiently evaluate and activate new contracts with carefully vetted local, minority-owned suppliers from one platform.

Conductiv will also add local and regional GPO contracts with vetted diverse suppliers and illuminate diverse supplier GPO contracting opportunities based on a healthcare organization’s historic spend. For minority-owned suppliers, working with Conductiv Contracts provides an opportunity to grow their businesses with regional and national healthcare providers. A member advisory committee will guide these collective efforts and investments.

«We’re committed to helping healthcare supply chains increase their diversity and inclusion efforts by connecting them to high-quality minority-owned suppliers,» Gormley added. «Our members have indicated their challenges in differentiating diverse spend and finding qualified diverse suppliers. To solve these challenges, our team is building off Conductiv’s category-defining integrated purchased services optimization suite and strengthening our data sources to ensure this is a simple and advantageous feature for both healthcare providers and diverse suppliers.»

For more information, please visit Conductiv.com.

About Conductiv
ConductivTM, formerly Medpricer, empowers supply chains to optimize their third-party services. As the only end-to-end third-party lifecycle improvement company, ConductivTM shares its strategic sourcing expertise and category best practices with multiple industries including healthcare, hospitality, government, real estate, transportation and education. The company has led more than 700 bids for more than 120 organizations, exceeding $4 billion in contracted value. Member projects have generated $800 million of documented savings or an average savings value of 24% to date. To learn how supply chains are transforming their savings strategy, visit Conductiv.com.

###

SOURCE Conductiv

NEW YORK, Aug. 11, 2020 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it is launching a Named Patient Program for its non-opioid bone metastases pain palliation drug, Strontium89 (Strontium Chloride Sr-89 Injection, USP). The Named Patient Program will be available to physicians and patients in the EU and throughout the world, and will be facilitated by Caligor Coghlan Pharma Services (CCPS).

Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer, and is agnostic of the primary tumor. Common primary tumors that metastasize to the bone include prostate, breast, lung, as well as others. In several multicenter, placebo-controlled trials in cancer patients with pain from bone metastases, pain relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo. Strontium89 is administered intravenously once every three months and for some patients can reduce or even eliminate the need for opioid analgesics; pain relief lasts from 2 – 5 months in most patients.

Use of Strontium89 in patients with evidence of seriously compromised bone marrow from previous therapy or disease infiltration is not recommended unless the potential benefit of the treatment outweighs its risks. Bone marrow toxicity is to be expected, particularly in white blood cells and platelets. The extent of toxicity is variable but effects are generally transient. In randomized studies of Strontium89, the majority of hematologic toxicity was mild to moderate (Grade 2 or less) and white blood cell and platelet counts remained within approximately 70% of pretreatment levels. For more information including Important Safety Information please visit the Strontium89 page on Qbiomed.com.

Over ten million people around the world suffer from pain associated with metastatic cancer in the bone and may benefit from Strontium89. For nearly two years, there has been little to no access to this vital therapy, after manufacturing ceased in December of 2018. Q BioMed is pleased that the Named Patient Program will ensure immediate global patient access to an important therapy for this patient population. In the meantime, Q BioMed is actively pursuing full regulatory and marketing approval for Strontium89 in all major markets worldwide.

Denis Corin, CEO of Q BioMed, said of the program, «We are very happy that Strontium89 is once again available worldwide, and that physicians have the ability to prescribe a safe, effective and non-opioid treatment to their bone metastasis pain patients regardless of their primary tumor type and notably beyond prostate cancer. We are actively working to ensure that Strontium89 is accessible to patients everywhere and to extend its relevance and use thorough additional clinical study.»

Any queries about the program and availability can be directed to info@qbiomed.com and at https://qbiomed.com/pipeline/sr89.

About Q BioMed Inc.

Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Please visit http://www.QBioMed.com and sign up for regular updates.

Media Contact Q BioMed:
Denis Corin
CEO

Investor Relations
+1(404) 995-6671
ir@qbiomed.com

About CCPS 

Caligor Coghlan Pharma Services is a global company focused on changing the healthcare paradigm by supporting medical device and pharmaceutical companies from concept to commercialisation. Providing bespoke development consulting, regulatory and strategic services, packaging and labelling for clinical trial and initial commercial launch, early access and compassionate use programs, and medication/product management, storage, and logistics for hospitals, pharmacies and global healthcare systems. Ensuring patients have access to life enhancing treatments worldwide.

Forward-Looking Statements:

This press release may contain «forward-looking statements» within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Please visit http://www.QBioMed.com and sign up for regular updates.

View original content:http://www.prnewswire.com/news-releases/q-biomed-announces-strontium89-will-be-available-as-of-september-2020-through-named-patient-program-for-bone-metastases-pain-palliation-in-eu-and-rest-of-world-301109633.html

SOURCE Q BioMed Inc.

ALPHARETTA, GA, Aug. 11, 2020 /PRNewswire/ — FDA has cleared MagVenture TMS Therapy^® for adjunct treatment of Obsessive-Compulsive Disorder (OCD). This marks the second indication in the US for the Danish medical device company MagVenture who is already FDA cleared for the treatment of major depressive disorder.

OCD is a mental health disorder characterized by unreasonable thoughts and fears (obsessions) which lead to repetitive behavior (compulsions). OCD can severely affect one’s daily life and routines and cause distress or even functional impairment. Although pharmaceutical and psychological interventions are available, some OCD patients experience limited results from these and need more therapeutic options.

Transcranial Magnetic Stimulation (TMS) uses magnetic pulses to stimulate a specific area in the brain in order to improve the OCD symptoms. TMS is a well-established, FDA cleared option for people suffering from treatment-resistant Major Depressive Disorder and available throughout the US at numerous psychiatric practices and hospitals. MagVenture TMS Therapy^® was FDA cleared for depression in 2015 and the first company to receive FDA clearance for the 3-minute Express TMS^® – the shortest TMS treatment currently available. 

MagVenture TMS Therapy is an adjunct treatment to existing OCD therapies which may involve pharmaceutical and behavioral therapy. It is an out-patient procedure with no systemic side effects. The treatment specifically targets the networks in the brain which are known to be particularly affected by OCD, including the deeper-lying structures.

«We have worked closely with brain researchers for well over 25 years, providing numerous TMS solutions to help advance the field of neuroscience – both basic and applied. Expanding the treatment options to include other indications than major depressive disorder, such as OCD, is one more important step towards helping more adult patients improve their mental health,» says VP of Sales, MagVenture Inc, Kerry Rome.   

MagVenture TMS Therapy^® FDA clearances: «As an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD)» and «Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.» 

MagVenture is a Danish medical device company specializing in non-invasive magnetic stimulation systems for the treatment of major depressive disorder and brain research. In 2018, MagVenture was the first TMS company to receive FDA clearance for Express TMS^®, reducing treatment time from the standard 37 minutes to just 3 minutes per session.

Kerry Rome, Vice President Sales, MagVenture Inc., USA: +1-310-213-2697

View original content:http://www.prnewswire.com/news-releases/magventure-receives-fda-clearance-for-ocd-301109815.html

SOURCE MagVenture